Rexahn Pharmaceuticals (RNN) Offers Results from Phase II Trial of Serdaxin for Major Depressive Disorder
Go back to Rexahn Pharmaceuticals (RNN) Offers Results from Phase II Trial of Serdaxin for Major Depressive Disorder| REXAHN PHARMACEUTICALS, Inc. (NYSE: RNN) | Delayed: 5.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.24 | 52 Week High | $0.48 | |||
| Open | $0.06 | 52 Week Low | $0.14 | |||
| Day High | $5.24 | P/E | N/A | |||
| Day Low | $5.24 | EPS | $-0.06 | |||
| Volume | 113,309 | |||||
